Literature DB >> 16376253

Waiting for hip arthroplasty: economic costs and health outcomes.

Jann M Fielden1, J M Cumming, J G Horne, P A Devane, A Slack, L M Gallagher.   

Abstract

This prospective cohort study of 153 patients aimed to determine the economic and health costs of waiting for total hip arthroplasty (THA). Health-related quality of life, using self-completed WOMAC and EQ-5D questionnaires, was assessed monthly from enrolment preoperatively to 6 months postsurgery. Monthly cost diaries were used to record costs. The mean waiting time was 5.1 months and mean total cost of waiting for surgery was NZ 4305 dollars(US 2876 dollars) per person (pp) (NZ 1 dollar = US 0.668 dollar). Waiting more than 6 months was associated with a higher total mean cost (NZ 4278 dollars/US 2858 dollars pp) than waiting less than 6 months (NZ 2828 dollars/US 1889 dollars pp; P < .01). Improvements from preoperative to postoperative WOMAC and EQ-5D scores were identified (P < or = .01). Waiting longer led to poorer physical function preoperatively (P < or = .01). Those with poor initial health status showed greater improvement in WOMAC (P = .0001) and EQ-5D (P = .003) measures by 6 months after surgery. Longer waits for total hip arthroplasty incur greater economic costs and deterioration in physical function while waiting.

Entities:  

Mesh:

Year:  2005        PMID: 16376253     DOI: 10.1016/j.arth.2004.12.060

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  12 in total

1.  Essay for the CIHR/CMAJ award: improving access to hip and knee replacement and its quality by adopting a new model of care in Alberta.

Authors:  Cyril Frank; Deborah Marshall; Peter Faris; Christopher Smith
Journal:  CMAJ       Date:  2011-03-21       Impact factor: 8.262

2.  [Direct costs of osteoarthritis].

Authors:  Ernst Wagner
Journal:  Wien Med Wochenschr       Date:  2011-01

3.  Time from Booking Until Appointment and Healthcare Utilization in Hand Surgery Patients with Discretionary Conditions.

Authors:  Michael Kuntz; Teun Teunis; Johann Blauth; David Ring
Journal:  J Hand Microsurg       Date:  2015-08-14

4.  Willingness of patients to change surgeons for a shorter waiting time for joint arthroplasty.

Authors:  Barbara Conner-Spady; Claudia Sanmartin; Geoffrey Johnston; John McGurran; Melissa Kehler; Tom Noseworthy
Journal:  CMAJ       Date:  2008-08-12       Impact factor: 8.262

5.  Health-related quality of life of day-case surgery patients: a pre/posttest survey using the EuroQoL-5D.

Authors:  Riitta Suhonen; Heli Virtanen; Katja Heikkinen; Kirsi Johansson; Anne Kaljonen; Tiina Leppänen; Sanna Salanterä; Helena Leino-Kilpi
Journal:  Qual Life Res       Date:  2007-12-12       Impact factor: 4.147

Review 6.  What is the current evidence of the impact on quality of life whilst waiting for management/treatment of orthopaedic/musculoskeletal complaints? A systematic scoping review.

Authors:  Joanne Morris; Asterie Twizeyemariya; Karen Grimmer
Journal:  Qual Life Res       Date:  2018-04-02       Impact factor: 4.147

7.  Obesity and racial characteristics drive utilization of total joint arthroplasty at a younger age.

Authors:  J Logan Brock; Atul F Kamath
Journal:  J Clin Orthop Trauma       Date:  2018-04-17

8.  Decline in Health-Related Quality of Life reported by more than half of those waiting for joint replacement surgery: a prospective cohort study.

Authors:  Ilana N Ackerman; Kim L Bennell; Richard H Osborne
Journal:  BMC Musculoskelet Disord       Date:  2011-05-23       Impact factor: 2.362

9.  Lower Urinary Tract Infection and Periprosthetic Joint Infection after Elective Primary Total Hip Arthroplasty.

Authors:  Chan Ho Park; Young-Kyun Lee; Kyung-Hoi Koo
Journal:  Hip Pelvis       Date:  2017-03-06

10.  High referral rates to secondary care by general practitioners in Norway are associated with GPs' gender and specialist qualifications in family medicine, a study of 4350 consultations.

Authors:  Unni Ringberg; Nils Fleten; Trygve S Deraas; Toralf Hasvold; OlavHelge Førde
Journal:  BMC Health Serv Res       Date:  2013-04-23       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.